The MarketReader Minute
The iShares Biotechnology ETF (IBB) fell about 0.4%, with losses across holdings including IQVIA, MannKind, Biogen, Waters, and Cytokinetics weighing on performance. The decline comes alongside a modest drop in the Russell 2000, reflecting softer sentiment toward biotech and small-cap growth stocks.
The MarketReader Minute
Biotech stocks moved higher, with (IBB) rising about 0.6% as expectations for increased pharmaceutical dealmaking and investment supported sentiment. Gains in Vertex, Moderna, Sarepta, IQVIA, and Iovance helped lift the sector alongside strength in small-cap equities.
The MarketReader Minute
Biotechnology stocks moved modestly higher, lifting the iShares Biotechnology ETF (IBB) by about 0.9% despite recent weekly declines across the sector. Gains in key holdings including Regeneron, Vaxcyte, Gilead, Amgen, and Twist Bioscience supported performance.
The MarketReader Minute
(IBB) rose 0.8% as positive regulatory developments and supportive macro data boosted sector sentiment. ImmunityBio’s ANKTIVA received approval from the Saudi Food and Drug Authority. Gains among major holdings, including Gilead, Amgen, Moderna, Incyte, and Sarepta, further supported the ETF.
The MarketReader Minute
(IBB) declined 0.6% Tuesday amid broad market volatility tied to weaker labor data. Sarepta Therapeutics led losses, offsetting stronger revenue results. Additional pressure came from Regeneron, Moderna, Alnylam, and Myriad Genetics, as investors weighed mixed earnings and macroeconomic uncertainty.
The MarketReader Minute
IBB fell 0.7% since Friday on heavy trading volume, even as it remains up 8.25% YTD and posted a 3.55% weekly gain. Regeneron slipped despite positive Phase 3 antibody trial data, while Moderna and BioNTech declined on lung cancer trial updates.
The MarketReader Minute
IBB advanced with notable contributions from Cytokinetics, Ionis, and Biogen, supported by fresh approvals and positive clinical data. Eupraxia’s trial news added momentum, offsetting recent weekly weakness and lifting year-to-date gains to 4.6%.
The MarketReader Minute
(IBB) fell, The FDA announced daily reporting on drug-related adverse events, a move aimed at modernizing surveillance. Still, key holdings like (REGN) and (MRNA) weighed heavily, offsetting positive headlines such as Amgen’s FDA approval.
The MarketReader Minute
IBB slipped 0.36% as Trump’s 100% tariff on foreign-made semiconductors stirred fears of broader sector fallout. Vertex and Vaxcyte weighed on performance, while inflation concerns and a soft labor market added pressure.
The MarketReader Minute
(IBB) slid 1.6% amid broader market worries as ISM Services PMI dropped to 50.1, sparking stagflation fears and renewed Fed rate cut speculation. Vertex and Amgen dragged the index lower ahead of earnings.
The MarketReader Minute
(IBB) declined 0.6% as markets absorbed the Fed’s steady rate stance and Q2 GDP growth of 3%. The removal of Vinay Prasad from the FDA was seen as a sector-positive move, though broader market weakness—evident in the Russell 2000’s drop—also weighed on IBB.
The MarketReader Minute
(IBB) edged down 0.2% Tuesday as mixed earnings and interest rate uncertainty weighed on sentiment. While the FDA's approval of SEPHIENCEâ„¢ for phenylketonuria marked a sector win, underperformance from MRNA, EXEL, IQV, CRSP, and BNTX dragged on the ETF.
